Lilly’s quarterly results Thursday, combined with Novo Nordisk’s unsolicited offer for a startup, confirm the $72 billion ...

Texas AG Ken Paxton accuses J&J and Kenvue of hiding Tylenol's autism risks for pregnant women in new lawsuit.

Takeda tightened its pipeline in the third quarter. Innovent Biologics reported a head-to-head win against semaglutide in a Chinese phase 3 trial. | Takeda tightened its pipeline in the third quarter.

Investing in biotechnology often feels like navigating a minefield. A single failed clinical trial can decimate a stock, ...

BridgeBio Pharma, Inc.'s Attruby (Acoramidis) delivers early, durable reductions in cumulative cardiovascular events. Learn ...

AstraZeneca, Eli Lilly and Merck committed $120 million to develop an advanced pharmaceutical manufacturing training center in Central Virginia.

Q3 2025 Management View CEO Stephan Tanda reported adjusted earnings per share of $1.62 for the third quarter, highlighting, "growth in our Pharma segment was driven by solid demand for proprietary ...

Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited genetic disorder affecting 1 in 31,000 people worldwide that can develop 500-1000 Basal Cell Carcinoma (BCC) ...

President Xi Jinping’s stranglehold on rare earths will give China unprecedented leverage to win concessions from the US ...

While the company’s sales outlook was otherwise rosy, Merck took sales hits on Gardisil, Proquad, Varivax and Vaxneuvance.

Shares in Mayne Pharma plunged by nearly a third on Friday after it emerged that Australia's treasurer was considering blocking a A$672 million ($435 million) offer for the company from now-reluctant ...

Eli Lilly, Zyrtec and Astellas Pharma recently invested in celeb partnerships to raise awareness about conditions.